ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 9 JULY 2025 at 13.00 EEST Inside information: Orion upgrades full-year outlook for 2025 Orion Corporation upgrades the full-year outlook for 2025 both for the part regarding net sales and operating profit. Orion’s product sales and royalty income have increased faster than expected during the first half of 2025, and this good development is anticipated to continue during the remainder of the year. Due to these reasons, Orion upgrades the full-ye ...

Life Sciences & Healthcare Equities Quarterly earnings: Where is the uncertainty? Developed Markets Half full or half empty? Investors remain focused on the uncertain regulatory outlook which in turn makes them more sensitive to the current challenges in the pharma sector, not only growth and profitability but also catalysts and capital deployment. On the other hand, in broad terms, companies seem less nervous about regulation, with commentary that interaction with the US administration is sensible. Further ...

Industry Overview - The Zacks Large Cap Pharmaceuticals industry includes major global companies developing multi-million-dollar drugs across various therapeutic areas such as neuroscience, cardiovascular, metabolism, rare diseases, immunology, and oncology [4] - Continuous innovation and significant investment in R&D are defining characteristics of these companies, with regular mergers and acquisitions being common [4][5] Current Market Conditions - The industry has shown resilience amid broader macroeconomic uncertainties, with a year-to-date performance increase of 3.9%, outperforming the Zacks Medical Sector's decline of 1.5% and the S&P 500's rise of 1.7% [14] - The current forward 12-month price-to-earnings (P/E) ratio for the industry is 15.65X, lower than the S&P 500's 21.89X and the Zacks Medical Sector's 19.31X, indicating potential value [17] Key Players and Performance - **Bayer**: Key drugs like Nubeqa and Kerendia are driving growth, with plans for new drug launches in 2025. The stock has risen 61.9% year-to-date, with 2025 EPS estimates increasing from $1.19 to $1.25 [20][22] - **Pfizer**: Strengthened its oncology position with the acquisition of Seagen. Despite challenges from declining COVID-19 product sales and patent expirations, non-COVID operational revenues are improving. The stock has lost 4.2% year-to-date, but 2025 EPS estimates have risen from $2.98 to $3.06 [25][26][28] - **Novartis**: Following the separation of Sandoz, it has a strong portfolio with drugs like Kisqali and Leqvio. The stock has risen 25.6% year-to-date, with 2025 EPS estimates increasing from $8.46 to $8.74 [31][32] - **AbbVie**: Successfully transitioned from the loss of exclusivity of Humira with new drugs like Skyrizi and Rinvoq. The stock has risen 9.5% year-to-date, with stable 2025 EPS estimates at $12.28 [35][37] - **Sanofi**: Dupixent is a key growth driver, supported by a strong vaccine portfolio. The stock has risen 6.3% year-to-date, with 2025 EPS estimates increasing from $4.43 to $4.56 [40][42] M&A and Innovation Trends - The industry is characterized by aggressive M&A activity, with large pharmaceutical companies acquiring innovative small and mid-cap biotech firms to enhance their pipelines [6][7] - Recent notable M&A activity includes Sanofi's offer to acquire Blueprint Medicines for approximately $9.5 billion, indicating continued robust M&A activity expected throughout the year [8]

2025 年 06 月 11 日 行业周报 看好/维持 医药 医药 板块持续跑赢大盘，关注后续创新药催化（附 CD73 靶点研究）(2025.06.03-2025.06.08) 走势比较 (20%) (10%) 0% 10% 20% 30% 24/6/11 24/8/22 24/11/2 25/1/13 25/3/26 25/6/6 | 君实生物 | 买入 | | --- | --- | | 华领医药-B | 买入 | | 奥锐特 | 买入 | | 同和药业 | 买入 | | 阳光诺和 | 买入 | | 泓博医药 | 买入 | | 福元医药 | 买入 | | 三生制药 | 买入 | | 京新药业 | 买入 | | 共同药业 | 增持 | | 亿帆医药 | 买入 | | 诺诚健华 | 买入 | | 诺思格 | 买入 | | 奥翔药业 | 买入 | | 科伦药业 | 买入 | | 国邦医药 | 买入 | | 来凯医药-B | 买入 | | 百利天恒 | 买入 | | 益方生物 | 买入 | | 皓元医药 | 买入 | | 普洛药业 | 买入 | | 信达生物 | 买入 | | 加科思-B | 买入 | 子行业评级 ...

上市公司回购热度不减 多家公募自购新发浮动费率基金 正在发行中的新模式浮动费率基金依然备受市场瞩目，多家基金公司更是用真金白银表达对旗下产品的 支持。6月3日，兴证全球基金发布公告，拟运用固有资金2000万元认购旗下兴证全球合熙混合型证券投 资基金。公开信息显示，该基金为首批新模式浮动费率基金之一，将于6月4日起发行。业内人士表示， 此次新模式浮动费率基金的发行有着积极的意义：一是产品明确锚定业绩比较基准，激励基金管理人不 断提升投资能力、完善投研体系，强化对长期超额收益的挖掘；二是费率与持有期挂钩，引导投资者长 期投资、理性投资；三是采用开放式运作模式，兼顾投资者长期投资与流动性管理的需求。（智通财 经） 数据显示，5月以来，截至6月3日，A股共440家上市公司对外发布回购相关公告。5月单月，发布新一 轮回购方案的有78家上市公司，数量仅次于4月份。同时，回购注销案例备受市场关注。回购增持贷款 方面，数据显示，自2024年10月以来，截至目前，A股共650家上市公司或重要股东获回购增持贷款， 回购增持贷款总金额约为1370亿元。（中国证券报） 理财公司再掀"降费潮" 万元理财一年管理费低至1元 理财行业掀起 ...

美国FDA批准拜耳前列腺癌药物达洛鲁胺 智通财经6月4日电，拜耳公司当地时间6月3日宣布，美国食品和药物管理局（FDA）已批准其口服雄激 素受体抑制剂Nubeqa™（达洛鲁胺）与雄激素剥夺疗法（ADT）联用，用于转移性去势抵抗性前列腺 癌。 ...

Core Viewpoint - Bayer's drug Nubeqa has received approval from the FDA for treating specific types of prostate cancer, based on positive results from a Phase 3 trial [1] Summary by Relevant Categories Drug Approval - Nubeqa is now approved for use in patients with certain types of prostate cancer [1] - The approval is based on a Phase 3 trial that demonstrated significant efficacy [1] Clinical Trial Results - The trial results indicated a 46% reduction in the risk of radiographic progression or death for patients receiving Nubeqa in combination with another therapy [1]

Core Insights - The U.S. FDA has approved darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), marking the third indication for this drug [2][9] - The approval is based on the Phase III ARANOTE trial, which demonstrated a 46% reduction in the risk of radiological progression or death compared to placebo plus ADT [2][10] - Darolutamide is already approved in over 85 markets globally for various indications related to prostate cancer, including mHSPC and non-metastatic castration-resistant prostate cancer (nmCRPC) [5][6] Company Overview - Darolutamide, marketed as Nubeqa®, achieved blockbuster status with annual sales of EUR 1.52 billion reported by Bayer for the full year of 2024 [6] - The drug is developed jointly by Orion and Bayer, indicating a strong collaboration in the oncology sector [6][11] - Orion Corporation has a robust clinical development program for darolutamide, exploring its efficacy across various stages of prostate cancer [13] Industry Context - Prostate cancer is the second most common cancer in men, with an estimated 1.5 million diagnoses and approximately 397,000 deaths worldwide in 2022 [4] - The incidence of prostate cancer is projected to rise to 2.9 million by 2040, highlighting the growing need for effective treatment options [4] - The ARANOTE trial involved 669 patients and assessed the efficacy and safety of darolutamide plus ADT, reinforcing the drug's established safety profile [7][8]

Shares of ORIC Pharmaceuticals (ORIC) surged more than 20% in the pre-market hours today after announcing potentially best-in-class preliminary efficacy and safety data from the ongoing early-stage study of its novel, once-daily candidate, ORIC-944, for prostate cancer. ORIC-944, in combination with AR inhibitors, J&J’s (JNJ) Erleada (apalutamide) and Bayer’s (BAYRY) Nubeqa (darolutamide), is being evaluated in the phase Ib study for treating patients with metastatic castration-resistant prostate cancer (mC ...

Core Insights - ORIC Pharmaceuticals announced promising preliminary efficacy and safety data for ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC) [1][3] - The company reported a 59% PSA50 response rate and a 24% PSA90 response rate in the ongoing Phase 1b trial, indicating substantial clinical activity [1][6] - A concurrent financing of $125 million is expected to extend the company's cash runway into the second half of 2027, supporting further development of ORIC-944 [10] Efficacy Data - The Phase 1b trial showed a confirmed PSA50 response rate of 47% and a PSA90 response rate of 24%, with responses observed across all dose levels of ORIC-944 [1][6][7] - The majority of patients are still ongoing with treatment, with several approaching one year or more on therapy [1][7] Safety Profile - ORIC-944 demonstrated a favorable safety profile, with most adverse events classified as Grade 1 or 2, primarily mild to moderate gastrointestinal issues [2][8] - Diarrhea was the most common treatment-related adverse event, occurring in 53% of patients, with only one Grade 3 event reported [8] Trial Design and Next Steps - The ongoing Phase 1b trial is designed to explore different doses of ORIC-944 in combination with apalutamide and darolutamide, with the primary objective of determining the recommended Phase 2 dose [4][9] - Following the completion of the dose exploration phase, the company plans to evaluate candidate doses for optimization in the second half of 2025, leading to a global Phase 3 trial expected to start in the first half of 2026 [9] Corporate Update - The $125 million financing is anticipated to close on May 29, 2025, and will support the company's operations through the primary endpoint readout of the first Phase 3 trial [10]